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Summary
Background Ending the global tobacco epidemic is a defining challenge in global health. Timely and comprehensive 
estimates of the prevalence of smoking tobacco use and attributable disease burden are needed to guide tobacco 
control efforts nationally and globally.
Methods We estimated the prevalence of smoking tobacco use and attributable disease burden for 204 countries and 
territories, by age and sex, from 1990 to 2019 as part of the Global Burden of Diseases, Injuries, and Risk Factors Study. 
We modelled multiple smoking-related indicators from 3625 nationally representative surveys. We completed systematic 
reviews and did Bayesian meta-regressions for 36 causally linked health outcomes to estimate non-linear dose-response 
risk curves for current and former smokers. We used a direct estimation approach to estimate attributable burden, 
providing more comprehensive estimates of the health effects of smoking than previously available.
Findings Globally in 2019, 1·14 billion (95% uncertainty interval 1·13–1·16) individuals were current smokers, who 
consumed 7·41 trillion (7·11–7·74) cigarette-equivalents of tobacco in 2019. Although prevalence of smoking had 
decreased significantly since 1990 among both males (27·5% [26·5–28·5] reduction) and females (37·7% [35·4–39·9] 
reduction) aged 15 years and older, population growth has led to a significant increase in the total number of smokers 
from 0·99 billion (0·98–1·00) in 1990. Globally in 2019, smoking tobacco use accounted for 7·69 million (7·16–8·20) 
deaths and 200 million (185–214) disability-adjusted life-years, and was the leading risk factor for death among 
males (20·2% [19·3–21·1] of male deaths). 6·68 million [86·9%] of 7·69 million deaths attributable to smoking 
tobacco use were among current smokers.
Interpretation In the absence of intervention, the annual toll of 7·69 million deaths and 200 million disability-adjusted 
life-years attributable to smoking will increase over the coming decades. Substantial progress in reducing the prevalence 
of smoking tobacco use has been observed in countries from all regions and at all stages of development, but a large 
implementation gap remains for tobacco control. Countries have a clear and urgent opportunity to pass strong, evidence-
based policies to accelerate reductions in the prevalence of smoking and reap massive health benefits for their citizens.
Funding Bloomberg Philanthropies and the Bill & Melinda Gates Foundation.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Over the past 30 years, more than 200 million deaths have 
been caused by smoking tobacco use, and annual 
economic costs due to smoking tobacco use exceed 
US$1 trillion.1,2 With more than 1 billion current smokers 
globally in 2019, these numbers are likely to increase over 
the coming decades. The enormous health and economic 
consequences of the global tobacco epidemic make 
tobacco control a clear and urgent public health priority.3 
Effective implementation and enforcement of tobacco 
control policies and inter ventions can both increase 
healthy life expectancy and decrease health-care costs.4–7 
Despite the clear benefits, progress in tobacco control has 
varied substantially across countries.
The first international public health treaty, the WHO 
Framework Convention on Tobacco Control (FCTC), 
entered into force and became an international binding 
law in 2005.8 Consensus on the importance of tobacco 
control led 182 countries to ratify the treaty, which 
outlines a suite of recommended demand-reduction 
tools. These tools include reducing affordability 
through taxation, passing smoke-free laws, mandating 
health warnings on packaging, and banning tobacco 
advertising, promotion, and sponsorship.9 15 years after 
the FCTC entered into force, a large implementation 
gap remains. WHO has monitored the implementation 
of the FCTC articles using the MPOWER framework 
for more than a decade.10 Over this period, only 
two countries, Brazil and Turkey, have implemented all 
the demand-reduction policies included in MPOWER 
at their highest level.10 Nonetheless, progress has been 
made in expanding coverage of best-practice policies, 
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with the number of countries implementing at least 
one best-practice policy increasing from 43 in 2007 
to 136 in 2018.10
The global importance of non-communicable diseases 
has led to their inclusion at the forefront of global 
progress targets, including a goal of 25% reduction in 
premature mortality from non-communicable diseases 
by 2025 outlined in the WHO global non-communicable 
disease monitoring framework and a third reduction 
by 2030 included in the UN Sustainable Development 
Goals (SDGs).11,12 Tobacco control has been identified 
as a crucial and necessary part of reaching these goals, 
with one in six non-communicable disease-related 
deaths being attributable to smoking tobacco use.13–17 As 
countries work towards meeting global progress targets 
for reducing the prevalence of smoking tobacco use and 
premature mortality from non-communicable diseases, 
timely data on the prevalence of smoking tobacco use 
and attributable disease are necessary to guide effective 
policy and planning.11,17
The public health significance of smoking tobacco 
use has resulted in a long tradition of estimating 
patterns of smoking tobacco use and its health 
effects.17–21 Estimates of the attri butable burden of 
smoking tobacco use have been included in the Global 
Burden of Diseases, Injuries, and Risk Factors Study 
(GBD) since its initial publication in 1997.22 Previous 
studies estimating the attributable burden of tobacco 
smoking have combined indirect estimation using the 
Smoking Impact Ratio method for cancers and chronic 
obstructive pulmonary disease, which uses observed 
lung cancer mortality to indirectly estimate the disease 
burden attributable to tobacco smoking, with direct 
estimation using lagged prevalence of daily smoking 
tobacco use for cardiovascular and circulatory diseases 
and all other health outcomes.20,23,24 For health out-
comes modelled using daily prevalence, risks among 
occasional smokers and former smokers were not 
included, and methods did not reflect well described 
dose-response associations between smoking intensity 
and risk of disease. For the health outcomes modelled 
using the Smoking Impact Ratio method, reliability 
was low in countries with either scare or poor quality 
data on lung cancer mortality and in countries with 
other important competing risks for lung cancer, such 
as air pollution.
The objective of this study, which is part of GBD 2019, 
was to update and improve previous estimates of global 
trends in the prevalence of tobacco smoking and 
tobacco smoking-attributable disease for 204 countries 
and territories, by age and sex, from 1990 to 2019. Using 
new methods and new data, we aimed to provide novel 
insights into patterns of smoking intensity and their 
association with health outcomes that are directly 
relevant to guiding tobacco control efforts nationally 
and globally. This manuscript was produced as part of 
the GBD Collaborator Network and in accordance with 
the GBD Protocol.
Research in context
Evidence before this study
The importance of smoking tobacco use as a risk factor has 
resulted in a long history of estimating its prevalence and 
health effects using a variety of epidemiological methods. 
WHO produces biennial updates to estimates of prevalence of 
smoking tobacco use and the status of tobacco control 
policies around the world. The most recent global analysis of 
the burden of disease attributable to smoking was published 
on the basis of results from The Global Burden of Diseases, 
Injuries, and Risk Factors Study (GBD) 2015.
Added value of this study
This study, which is based on results from GBD 2019, updates 
and improves on previous estimates of the prevalence of 
smoking tobacco use and attributable disease burden. 
Compared with the GBD 2015 smoking prevalence and disease 
burden study, we have included more than 800 additional data 
sources on prevalence of smoking. In terms of methods, 
we developed and implemented a new unified approach to 
estimating the disease burden attributable to smoking tobacco 
use that addresses limitations of previous methods with direct 
estimation for all 36 causally linked health outcomes and 
reflecting dose-response associations among both current and 
former smokers. We estimated new continuous exposure 
distributions, including distributions of age of initiation, 
cigarette-equivalents of tobacco smoked per day, pack-years, 
and years since cessation, and new cause-specific dose-response 
relative risk curves among both current and former smokers. 
These changes improve the reliability of estimates, particularly 
in low-income and middle-income countries, allow for 
disaggregation of disease burden by intensity of exposure, and 
also generate a multitude of new inputs that can be used by 
researchers and decision makers to inform and improve 
modelling studies.
Implications of all the available evidence
Smoking remains one of the most important risk factors for 
premature mortality and morbidity globally. Progress in 
reducing the prevalence of smoking tobacco use has varied 
widely, as has commitment to tobacco control across 
countries. Of concern, progress in many countries has slowed 
in the past 10 years and, with population growth, the total 
number of global smokers continues to increase. All countries 
must urgently adopt and enforce a comprehensive package of 
evidence-based policies to reduce the prevalence of current 
smoking and prevent initiation, particularly among 
adolescents and young adults.
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Methods
Overview
As part of GBD 2019, we estimated the burden of disease 
attributable to smoking of tobacco using the comparative 
risk assessment framework for 204 countries and 
territories, by age and sex, and from 1990 to 2019. We 
used direct estimation methods for 36 causally linked 
health outcomes that show dose-response associations 
among both current and former smokers. Here, we 
summarise the key analytical steps: estimating prevalence 
of cur rent and former use of smoking tobacco; modelling 
distributions of cigarette-equivalents of tobacco smoked 
per day, pack-years, and years since cessation; estimating 
dose-response risk curves for the 36 health outcomes; and 
calculating population-attributable fractions (PAFs). Full 
details on each analytical step are provided in appendix 1 
(pp 3–28). This study adheres to the Guidelines for 
Accurate and Transparent Health Estimates Reporting 
(GATHER).25
Prevalence of smoking tobacco use
We systematically identified and extracted data from 
3625 nationally representative surveys, including both 
multinational and country-specific surveys, covering 
200 of the 204 countries and territories included in the 
analysis. 171 (86%) of 200 countries had at least five 
surveys for the period 1980–2019, and 141 (71%) countries 
had data available from 2015 or later. Data for 1980–89 
were used to inform time trends, but are not reported in 
the results. For countries without data, estimates were 
entirely based on models. We extracted data for 
individuals aged 10 years and older, and used data on 
individuals aged 10–14 years to inform model estimates; 
however, we report prevalence among individuals 
aged 15 years and older. Additional infor mation on 
identification of sources, inclusion criteria, and data 
extraction are in appendix 1 (pp 11–12). A complete list of 
data sources used in our analysis is available through the 
Global Health Data Exchange (GHDx).
To ensure that all data included in the model were 
comparable, and to prevent compositional bias from 
affecting our estimates, we used two key data processing 
steps. First, we used linear regression to adjust data from 
surveys that only reported non-reference case definitions. 
Our reference case definitions were current use of any 
smoked tobacco product on a daily or occasional basis, 
and former use of any smoked tobacco product. We 
included all smoked tobacco products—eg, cigarettes, 
pipes, cigars, shisha, bidis, kreteks, and other local 
smoked tobacco products. We did not include smokeless 
tobacco, electronic cigarettes (also known as e-cigarettes), 
vaping products, or heated tobacco products. Risks 
from chewing tobacco and second-hand smoke are 
included as other risk factors in GBD and are outside the 
scope of this study.1,26
Second, we split data reported in aggregated age 
groups or as both sexes combined into our standard 
5-year age-sex groups. To estimate an age-sex pattern 
that reflects observed spatial and temporal variation, we 
estimated a preliminary prevalence model using only 
data available in our standard age-sex groups. We then 
used the estimated age-sex pattern, which varied by 
location and year, to split aggregated data, a process 
that also allowed us to propagate uncertainty in the age-
sex pattern. These methods have been previously 
published,19,20,27 and full details are in appendix 1 
(pp 13, 20).
We used spatiotemporal Gaussian process regression 
(ST-GPR) to model prevalence of both current and former 
smoking tobacco use (appendix 1 p 21). This modelling 
approach has been used extensively in GBD to estimate 
time-varying risk factors.27,28 Briefly, the model was 
estimated in three stages. First, the level and trend were 
set in countries using linear regression based on 
covariates. Next, the first-stage estimates were adjusted by 
adding residuals with decaying weights across time, age, 
and location. Finally, the second-stage estimates were 
used as the prior in Gaussian process regression, which 
further refined the model fit and incorporated both data 
and model uncertainty. 1000 draws from the posterior 
distribution were retained and used for analysis. We report 
results with the 95% uncertainty interval (UI) of estimates 
based on the 2·5th and 97·5th percentile of draws.
Exposure distribution
Estimates of prevalence of current and former smoking 
tobacco use define the full population at risk, but risk of 
disease varies within these groups on the basis of 
intensity of smoking and length of time since cessation. 
To incorporate these differences in risk in our 
estimation framework, we modelled continuous 
exposure distribu tions among both current and former 
smokers. Among current smokers, we estimated two 
distributions: cross-sectional cigarette-equivalents of 
tobacco per smoker per day and cumulative pack-years 
across their lifetime. Among former smokers, we 
estimated the distribution of the number of years since 
cessation. To account for heterogeneity in smoked 
tobacco products, we use a standard unit of cigarette-
equivalents of tobacco. We converted non-cigarette 
tobacco products to cigarette-equivalents on the basis of 
amount of tobacco (in g), assuming 1 g of tobacco per 
cigarette. Estimates of cigarette-equivalents consumed 
per smoker per day combine two sources of information: 
self-reported smoking patterns from household surveys 
and supply-side data on country-level consumption 
available from the Food and Agriculture Organiza tion of 
the UN (1961–2013), the US Department of Agriculture 
(1960–2005), and Euromonitor (2002–17). Details on 
the modelling process for the supply-side data and 
approach to integrating the two sources of information 
are in appendix 1 (pp 22–23).
Using estimates of cigarette-equivalents per smoker 
per day by location, age, and sex from 1960 to 2019, 
See Online for appendix 1
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along with estimates of the distribution of initiation 
age, we reconstructed individual smoking histories on 
the basis of birth cohort smoking patterns to estimate 
population-level distributions of pack-years consumed. 
This approach is crucial to estimation of the burden 
of health outcomes that are linked to long-term 
cumulative exposure, because assumptions of constant 
consumption on the basis of cross-sectional patterns 
result in underestimation of risk at older ages and 
overestimation of risk at younger ages.
Where available, we extracted age of cessation or years 
since cessation from surveys to estimate a distribution 
of years since cessation among former smokers. 
Distributions of years since cessation, cigarette-
equivalents per smoker per day, and age of initiation 
were based on an ensemble of underlying distribution 
shapes, parameterised by means (estimated using 
ST-GPR) and SDs (predicted from means using linear 
regression). An expanded description of the ensemble 
distribution strategy is in appendix 1 (p 24).
Dose-response risk curves
Previous estimates of smoking-attributable burden in 
GBD relied on dichotomous exposures, despite well 
documented dose-response associations. To address 
this limitation, we estimated dose-response risk curves 
for both current and former smokers for 36 health 
outcomes using meta-regression (appendix 1 p 26). 
This process involved an extensive systematic review, 
covering 71 996 total search string hits, from which 
902 prospective cohort and case-control studies were 
found to be eligible and from which data were extracted 
(Preferred Reporting Items for Systematic reviews and 
Meta-Analyses [PRISMA] diagrams for each outcome 
are in appendix 1 [pp 31–66]). For cancers and chronic 
obstructive pulmonary disease, we used pack-years as 
the exposure, allowing risk to reflect both duration and 
dose (cigarette-equivalents per day) of exposure. For 
cardiovascular and circulatory diseases and all other 
health outcomes, we used cigarette-equivalents per 
smoker per day as the exposure among current smokers, 
because dose is generally thought to be more important 
than duration of exposure for these health outcomes. 
We used the Disease Modelling Ordinary Differential 
Equation (DisMod ODE) solver to fit non-linear 
Bayesian meta-regressions for each health outcome.29,30 
Due to a paucity of data on relative risks among 
individuals younger than 30 years, we attributed 
outcomes to individuals aged 30 years and older, an 
approach consistent with previous GBD studies.
Among former smokers, risk decreases with an 
increasing number of years since cessation, but the level 
of risk also depends on previous smoking history. 
To control for differences in smoking history across 
the populations included in the meta-regressions, we 
adjusted reported relative risk estimates to standardise 
the risk at the time of cessation (appendix 1 pp 26–28).30
Population attributable fractions
Inputs to estimation of PAFs included prevalence of 
current and former smoking tobacco use, continuous 
exposure distributions, relative risks, and the theoretical 
minimum risk exposure level. For smoking tobacco 
use, the theoretical minimum risk exposure level is 
never smoking. The PAF equation is specified in 
appendix 1 (p 28). Because the risk reduction curves for 
former smokers must account for two dimensions—
years since cessation and intensity of smoking before 
cessation—we scaled the risk reduction curves for former 
smokers to match their starting relative risk (when years 
since cessation equals zero) to the exposure-weighted 
relative risk among current smokers in that population. 
We combined global dose-response risk curves with 
country-year-age-sex-specific continuous exposure dis-
tributions so we could capture differences in risk across 
countries that result from heterogeneous smoking 
patterns. Exposures were lagged on the basis of the 
average length of follow-up across studies included in 
the meta-regressions (appendix 1 p 28). We calculated 
attributable burden by multiplying PAFs with cause-
specific deaths by location, year, age, and sex, available 
from GBD 2019.31 Using the distributive property of 
PAFs, we also partitioned out smoking-attributable 
deaths by exposure categories.32
Using our PAF estimates, we calculated the number 
of smoking attributable deaths, disability-adjusted life-
years (DALYs), years of life lost (YLLs), and years lived 
with disability (YLDs). We further calculated the ratio of 
YLLs to YLDs by country and examined associations 
of this ratio with Socio-demographic Index level. For 
analyses by country income level, we used World Bank 
income groups.
We did all analyses using R (versions 3.1–3.6) and 
Python (version 2.7).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
Globally, there were 1·14 billion (95% UI 1·13–1·16)
current smokers in 2019. Age-standardised prevalence of 
current use of smoking tobacco among individuals 
aged 15 years and older was 32·7% (32·3–33·0) among 
males and 6·62% (6·43–6·83) among females. Age-
standardised prevalence among males aged 15 years and 
older ranged from 7·33% (6·56–8·20) in Peru to 64·6% 
(62·7–66·6) in Timor-Leste, and among females from 
0·696% (0·517–0·906) in Eritrea to 42·3% (36·5–48·4) 
in Greenland (table). Smoking prevalence exceeded 20% 
among males in 151 countries and among females in 
42 countries (table). Among individuals aged 15 years 
and older, countries with the highest prevalence of 
smoking tobacco use among males were mostly in Asia 
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and Oceania (appendix 2 p 83), whereas countries with 
the highest prevalence of smoking tobacco use among 
females were mostly in Europe and Oceania (appendix 2 
p 84). Among the 159 countries with a population 
exceeding 1 million, the highest prevalence of smoking 
tobacco use in males aged 15 years and older was 
observed in Timor-Leste, Indonesia, Armenia, Jordan, 
and Georgia, and the highest prevalence of smoking 
tobacco use among females aged 15 years and older was 
observed in Serbia, Chile, Croatia, Bulgaria, and Greece 
(table). The ten countries with the largest number of 
tobacco smokers in 2019, together comprising nearly 
two-thirds of the global tobacco smoking popula-
tion, were China, India, Indonesia, the USA, Russia, 
Bangladesh, Japan, Turkey, Vietnam, and the Philippines 
(appendix 2 pp 85–93); 341 million (30%) of 1·14 billion 
tobacco smokers globally lived in China in 2019.
Since 1990, global age-standardised prevalence of 
smoking tobacco use among males aged 15 years and 
older decreased by 27·5% (95% UI 26·5–28·5) and 
among females decreased by 37·7% (35·4–39·9), with 
variable progress across countries (table). Prevalence of 
smoking tobacco use among males aged 15 years and 
older decreased significantly between 1990 and 2019 in 
135 countries (66%), but decreased significantly among 
females in only 68 countries (33%). The largest decreases 
were observed in Brazil, where prevalence decreased 
by 72·5% (70·1–74·7) among males and by 74·7% 
(71·2–78·0) among females. Among individuals aged 
15 years and older, prevalence of smoking tobacco use 
See Online for appendix 2
Age-standardised prevalence, 2019 Percentage change, 1990–2019
Females Males Females Males
Global 6·62 (6·43 to 6·83) 32·7 (32·3 to 33·0) –37·7 (–39·9 to –35·4) –27·5 (–28·5 to –26·5)
Central Europe, eastern Europe, 
and central Asia
15·5 (14·9 to 16·2) 39·5 (38·9 to 40·0) –4·37 (–10·2 to 2·00) –21·6 (–23·2 to –20·0)
Central Asia 3·79 (3·45 to 4·18) 34·3 (33·5 to 35·1) –5·97 (–19·7 to 7·78) –12·3 (–15·1 to –9·61)
Armenia 3·10 (2·48 to 3·79) 55·3 (53·6 to 57·0) –5·19 (–33·9 to 35·0) –8·42 (–13·1 to –3·89)
Azerbaijan 2·50 (1·86 to 3·30) 43·6 (41·9 to 45·2) 30·8 (–13·7 to 91·7) –1·55 (–8·50 to 5·78)
Georgia 7·03 (5·97 to 8·15) 51·8 (50·0 to 53·6) 11·3 (–16·7 to 45·2) 5·80 (–0·933 to 13·6)
Kazakhstan 7·69 (6·46 to 9·16) 43·2 (41·3 to 45·0) 2·88 (–25·3 to 33·1) –14·9 (–19·9 to –10·0)
Kyrgyzstan 4·65 (3·77 to 5·63) 43·6 (41·7 to 45·5) 49·0 (7·52 to 105) –5·39 (–10·5 to –0·251)
Mongolia 8·26 (6·86 to 9·84) 51·7 (49·6 to 53·9) 44·4 (7·67 to 88·9) 11·0 (4·24 to 18·5)
Tajikistan 1·29 (0·982 to 1·68) 16·9 (15·7 to 18·3) –41·7 (–61·7 to –15·0) –45·8 (–51·7 to –39·4)
Turkmenistan 3·05 (2·34 to 3·91) 21·6 (19·8 to 23·4) –37·4 (–58·3 to –9·91) –46·5 (–52·2 to –40·4)
Uzbekistan 1·94 (1·48 to 2·48) 24·8 (23·1 to 26·6) 47·9 (–0·335 to 117) 36·3 (19·6 to 53·5)
Central Europe 25·9 (25·0 to 26·7) 35·8 (35·1 to 36·4) –8·47 (–13·0 to –3·96) –24·7 (–26·5 to –22·8)
Albania 11·9 (9·87 to 14·2) 51·5 (49·7 to 53·1) 85·0 (35·1 to 145) 25·4 (16·5 to 34·3)
Bosnia and Herzegovina 30·5 (26·8 to 34·2) 45·1 (42·6 to 47·5) 41·1 (16·1 to 70·3) 17·5 (7·49 to 27·7)
Bulgaria 32·5 (29·5 to 35·4) 42·5 (40·4 to 44·6) –16·2 (–29·5 to –0·400) –20·4 (–26·0 to –14·9)
Croatia 32·6 (29·9 to 35·5) 39·1 (37·2 to 41·0) –11·7 (–23·5 to 0·755) –17·6 (–23·3 to –11·8)
Czech Republic 23·2 (21·3 to 25·2) 34·1 (32·5 to 35·6) –20·2 (–29·1 to –9·61) –21·7 (–27·5 to –15·9)
Hungary 26·5 (23·8 to 29·2) 34·2 (32·0 to 36·1) –18·4 (–29·4 to –6·32) –21·7 (–27·2 to –15·6)
Montenegro 32·7 (30·3 to 35·2) 37·5 (35·7 to 39·3) 0·505 (–15·8 to 20·0) –8·35 (–16·0 to –0·294)
North Macedonia 31·0 (28·3 to 33·9) 47·1 (45·0 to 49·2) 4·38 (–14·7 to 25·1) –2·24 (–9·31 to 5·48)
Poland 24·4 (22·5 to 26·3) 31·8 (30·4 to 33·3) –17·8 (–25·8 to –9·17) –40·5 (–43·6 to –37·2)
Romania 23·5 (21·7 to 25·5) 38·4 (36·8 to 40·0) 8·91 (–5·85 to 25·1) –18·8 (–24·7 to –12·8)
Serbia 37·8 (34·5 to 41·1) 38·8 (36·9 to 40·8) 20·3 (2·25 to 39·8) –6·30 (–13·4 to 1·34)
Slovakia 20·9 (18·7 to 23·3) 33·3 (31·2 to 35·3) –14·9 (–31·4 to 4·94) –23·3 (–30·0 to –16·2)
Slovenia 24·9 (22·6 to 27·4) 29·8 (28·0 to 31·5) 9·05 (–11·3 to 30·7) –11·0 (–19·1 to –1·45)
Eastern Europe 15·6 (14·4 to 17·0) 44·7 (43·7 to 45·8) 15·9 (2·24 to 31·3) –19·4 (–22·0 to –16·8)
Belarus 23·6 (20·7 to 26·6) 50·2 (47·9 to 52·5) 31·5 (0·570 to 69·1) –5·15 (–11·8 to 1·42)
Estonia 18·9 (17·2 to 20·7) 31·7 (30·2 to 33·1) –12·9 (–24·8 to –1·42) –28·3 (–32·5 to –23·9)
Latvia 21·3 (19·3 to 23·4) 46·9 (45·2 to 48·7) –3·33 (–18·8 to 15·5) –12·9 (–17·4 to –7·98)
Lithuania 20·3 (18·4 to 22·6) 37·9 (36·1 to 39·8) 28·9 (10·4 to 50·4) –18·5 (–23·9 to –12·9)
Moldova 7·20 (5·93 to 8·68) 40·6 (38·6 to 42·7) 11·7 (–17·2 to 47·7) 3·88 (–4·24 to 13·0)
Russia 15·5 (13·9 to 17·3) 45·6 (44·1 to 47·0) 26·1 (5·67 to 49·7) –17·6 (–21·1 to –13·9)
Ukraine 14·4 (12·7 to 16·3) 42·0 (40·3 to 43·6) –7·85 (–26·0 to 12·4) –28·3 (–32·1 to –24·4)
(Table continues on next page)
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Age-standardised prevalence, 2019 Percentage change 1990–2019
Females Males Females Males
(Continued from previous page)
High income 17·6 (17·1 to 18·2) 26·9 (26·4 to 27·3) –28·8 (–31·2 to –26·2) –32·2 (–33·4 to –31·0)
Australasia 14·5 (12·7 to 16·5) 16·7 (15·6 to 17·9) –46·5 (–53·1 to –39·0) –46·2 (–50·0 to –42·3)
Australia 14·4 (12·2 to 16·7) 16·4 (15·1 to 17·8) –46·8 (–54·9 to –38·0) –48·1 (–52·4 to –43·7)
New Zealand 15·2 (13·9 to 16·5) 18·4 (17·5 to 19·4) –44·8 (–49·8 to –39·5) –35·6 (–39·5 to –31·4)
High-income Asia Pacific 8·48 (7·48 to 9·64) 35·9 (34·4 to 37·3) –25·6 (–35·7 to –14·7) –36·9 (–39·7 to –34·0)
Brunei 5·39 (4·28 to 6·78) 28·5 (26·1 to 31·2) –31·3 (–50·9 to –7·75) –33·3 (–40·4 to –25·8)
Japan 10·2 (8·71 to 11·9) 33·4 (31·4 to 35·5) –23·6 (–35·2 to –9·65) –41·7 (–45·3 to –38·0)
Singapore 6·82 (5·38 to 8·41) 20·6 (18·9 to 22·4) –32·6 (–52·1 to –8·90) –31·3 (–39·6 to –22·5)
South Korea 5·21 (4·14 to 6·58) 42·5 (40·1 to 44·7) –18·4 (–42·8 to 11·5) –25·2 (–30·4 to –19·5)
High-income North America 15·3 (14·1 to 16·7) 19·7 (18·8 to 20·7) –39·9 (–44·8 to –34·5) –31·8 (–35·3 to –28·2)
Canada 15·9 (13·4 to 18·6) 18·3 (16·8 to 19·8) –48·2 (–56·5 to –38·9) –46·8 (–51·7 to –42·0)
Greenland 42·3 (36·5 to 48·4) 44·1 (40·9 to 47·3) –5·32 (–21·0 to 13·6) –10·2 (–18·0 to –2·05)
USA 15·3 (13·9 to 16·7) 19·9 (18·8 to 21·0) –38·7 (–44·2 to –32·7) –29·8 (–33·7 to –25·7)
Southern Latin America 23·3 (21·2 to 25·3) 31·3 (29·9 to 32·7) –20·0 (–31·2 to –8·02) –17·2 (–22·8 to –11·3)
Argentina 19·6 (17·3 to 22·2) 29·2 (27·4 to 31·0) –22·6 (–37·9 to –4·07) –17·5 (–25·7 to –7·94)
Chile 32·7 (28·7 to 36·6) 36·2 (33·9 to 38·4) –12·7 (–27·0 to 4·89) –13·0 (–20·6 to –4·91)
Uruguay 23·1 (19·4 to 26·7) 31·0 (28·8 to 33·3) –18·1 (–33·7 to –0·553) –23·0 (–30·0 to –14·8)
Western Europe 22·7 (22·0 to 23·4) 28·8 (28·2 to 29·3) –24·2 (–26·7 to –21·8) –28·8 (–30·2 to –27·4)
Andorra 24·4 (19·6 to 29·5) 31·4 (28·6 to 34·2) –19·8 (–37·9 to 1·56) –25·2 (–32·8 to –17·2)
Austria 26·1 (23·4 to 29·0) 36·1 (34·0 to 38·3) –10·5 (–20·2 to 0·384) –14·2 (–19·9 to –8·34)
Belgium 21·4 (19·6 to 23·3) 24·9 (23·6 to 26·2) –28·5 (–35·6 to –21·1) –39·3 (–43·1 to –35·6)
Cyprus 21·3 (18·7 to 24·3) 44·8 (42·6 to 47·1) –11·6 (–30·8 to 9·57) –5·43 (–12·5 to 2·85)
Denmark 22·6 (20·6 to 24·8) 22·7 (21·3 to 24·1) –49·5 (–54·0 to –44·4) –49·2 (–52·3 to –45·7)
Finland 18·1 (16·3 to 20·3) 24·8 (23·3 to 26·2) –31·2 (–39·3 to –21·5) –27·9 (–32·3 to –23·2)
France 31·3 (28·8 to 33·9) 36·9 (35·1 to 38·6) –1·18 (–9·35 to 7·54) –17·2 (–21·4 to –12·9)
Germany 23·0 (21·1 to 24·9) 29·9 (28·4 to 31·4) –18·0 (–25·2 to –10·3) –20·7 (–25·2 to –16·2)
Greece 32·2 (29·5 to 35·1) 44·1 (42·3 to 46·1) –0·620 (–9·99 to 8·67) –18·4 (–22·2 to –14·5)
Iceland 15·1 (13·1 to 17·5) 15·8 (14·7 to 17·1) –47·7 (–56·6 to –37·8) –51·4 (–55·8 to –46·3)
Ireland 22·8 (20·4 to 25·3) 21·9 (20·2 to 23·6) –27·8 (–35·7 to –19·6) –38·7 (–43·8 to –33·7)
Israel 14·9 (12·8 to 17·2) 26·4 (24·6 to 28·3) –39·8 (–51·2 to –27·4) –33·8 (–39·7 to –27·9)
Italy 18·9 (17·3 to 20·6) 27·3 (25·8 to 28·8) –28·1 (–34·5 to –21·2) –30·5 (–34·6 to –26·3)
Luxembourg 21·3 (19·3 to 23·3) 26·2 (24·5 to 28·0) –27·9 (–36·3 to –19·1) –31·6 (–36·8 to –25·4)
Malta 22·0 (19·2 to 24·9) 26·9 (24·9 to 28·8) –15·0 (–30·9 to 2·21) –36·0 (–41·9 to –29·5)
Monaco 23·6 (18·9 to 28·6) 29·0 (26·4 to 31·7) –19·5 (–38·7 to 2·21) –24·9 (–32·9 to –15·7)
Netherlands 20·4 (18·6 to 22·2) 25·0 (23·6 to 26·4) –46·8 (–51·7 to –41·5) –42·4 (–46·0 to –38·9)
Norway 16·5 (14·3 to 18·9) 20·2 (18·7 to 22·0) –57·6 (–63·9 to –50·4) –49·8 (–54·4 to –44·9)
Portugal 22·4 (20·2 to 24·7) 33·4 (31·7 to 35·0) 30·6 (16·4 to 45·4) –18·7 (–23·1 to –14·2)
San Marino 18·1 (15·2 to 21·5) 21·6 (19·7 to 23·4) –36·0 (–50·7 to –18·3) –40·5 (–47·3 to –33·4)
Spain 24·6 (22·6 to 26·8) 30·7 (29·1 to 32·5) –23·6 (–30·2 to –16·3) –39·6 (–42·9 to –36·0)
Sweden 14·4 (12·6 to 16·5) 12·4 (11·3 to 13·5) –47·1 (–54·5 to –38·7) –44·6 (–50·0 to –38·8)
Switzerland 23·4 (20·7 to 26·3) 29·3 (27·2 to 31·2) –18·9 (–28·6 to –8·35) –23·5 (–28·6 to –18·4)
UK 18·1 (16·3 to 19·9) 21·7 (20·4 to 22·9) –42·5 (–48·4 to –36·6) –35·7 (–39·7 to –32·0)
Latin America and Caribbean 7·64 (7·16 to 8·10) 17·1 (16·6 to 17·5) –59·6 (–62·5 to –56·5) –52·3 (–53·9 to –50·6)
Andean Latin America 4·84 (4·25 to 5·48) 14·0 (13·3 to 14·6) –17·4 (–33·4 to 0·994) –16·9 (–23·1 to –10·5)
Bolivia 7·31 (5·94 to 8·85) 18·2 (16·8 to 19·7) –0·326 (–29·1 to 36·6) –7·58 (–18·9 to 5·09)
Ecuador 4·97 (4·14 to 5·98) 24·7 (23·5 to 25·9) –18·1 (–38·7 to 7·54) –8·37 (–17·2 to 0·777)
Peru 4·02 (3·22 to 4·95) 7·33 (6·56 to 8·20) –23·2 (–47·1 to 9·24) –35·4 (–45·4 to –24·6)
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Caribbean 8·65 (7·76 to 9·55) 19·6 (18·9 to 20·4) –37·1 (–45·9 to –26·9) –30·9 (–34·6 to –27·0)
Antigua and Barbuda 5·56 (4·29 to 6·97) 12·5 (11·1 to 14·1) 31·5 (–6·42 to 81·9) 31·4 (11·8 to 52·7)
The Bahamas 3·18 (2·51 to 4·04) 11·4 (10·4 to 12·6) –11·4 (–38·4 to 27·1) –0·304 (–13·6 to 15·5)
Barbados 4·61 (3·60 to 5·88) 13·9 (12·6 to 15·5) –3·25 (–34·2 to 38·0) –15·4 (–26·6 to –2·65)
Belize 4·13 (3·18 to 5·24) 22·5 (20·4 to 24·6) 9·24 (–25·9 to 50·3) 1·95 (–11·1 to 15·7)
Bermuda 8·32 (6·80 to 10·2) 18·1 (16·5 to 19·9) –2·45 (–28·8 to 33·4) –0·776 (–13·6 to 14·7)
Cuba 15·3 (12·7 to 17·9) 31·8 (29·4 to 34·4) –34·2 (–49·2 to –15·1) –25·9 (–32·8 to –18·2)
Dominica 6·29 (4·82 to 8·04) 15·1 (13·4 to 16·8) –6·88 (–35·3 to 27·5) –2·73 (–17·0 to 13·5)
Dominican Republic 9·27 (7·70 to 10·9) 13·7 (12·6 to 14·9) –21·0 (–39·6 to 1·18) –7·15 (–18·0 to 5·97)
Grenada 5·39 (4·16 to 6·85) 17·7 (15·8 to 19·6) 2·67 (–30·5 to 44·3) 7·33 (–7·82 to 23·7)
Guyana 4·20 (3·32 to 5·19) 24·9 (23·3 to 26·8) –9·62 (–36·7 to 22·6) 6·45 (–6·41 to 20·9)
Haiti 2·65 (2·05 to 3·36) 10·1 (9·22 to 11·0) –48·6 (–65·2 to –27·5) –45·8 (–52·6 to –38·4)
Jamaica 6·82 (5·73 to 8·09) 20·1 (18·5 to 21·8) –21·8 (–40·1 to 0·233) –26·5 (–34·8 to –17·5)
Puerto Rico 8·57 (7·42 to 9·87) 16·0 (14·9 to 17·2) –14·2 (–31·8 to 6·44) –18·3 (–26·4 to –8·88)
Saint Kitts and Nevis 2·87 (2·16 to 3·75) 10·5 (9·30 to 11·8) –0·0613 (–32·4 to 41·3) 1·56 (–15·0 to 20·1)
Saint Lucia 5·27 (4·17 to 6·49) 19·2 (17·4 to 21·1) –14·2 (–39·3 to 18·3) –13·3 (–24·0 to –0·879)
Saint Vincent and the 
Grenadines
4·24 (3·22 to 5·53) 20·3 (18·5 to 22·1) 2·04 (–28·9 to 41·4) –4·93 (–15·8 to 7·45)
Suriname 8·85 (7·07 to 11·0) 34·2 (31·7 to 36·6) –25·5 (–46·9 to 0·950) –17·7 (–25·5 to –8·96)
Trinidad and Tobago 8·17 (6·44 to 10·1) 28·9 (26·6 to 31·2) –7·88 (–34·0 to 26·3) –12·7 (–22·4 to –2·34)
Virgin Islands 4·98 (3·98 to 6·18) 8·28 (7·38 to 9·22) –24·3 (–46·3 to 2·89) –23·3 (–34·3 to –9·97)
Central Latin America 8·72 (8·04 to 9·48) 22·7 (22·0 to 23·4) –42·2 (–49·0 to –34·4) –40·1 (–42·6 to –37·5)
Colombia 9·71 (8·42 to 11·2) 14·7 (13·6 to 15·9) –33·3 (–49·3 to –13·6) –53·6 (–58·7 to –48·1)
Costa Rica 7·19 (5·93 to 8·67) 15·3 (14·1 to 16·6) –48·2 (–60·7 to –32·1) –45·9 (–52·2 to –38·8)
El Salvador 3·70 (2·91 to 4·63) 17·3 (15·8 to 18·9) 36·9 (–5·05 to 87·8) 34·3 (15·4 to 55·2)
Guatemala 4·34 (3·43 to 5·41) 20·5 (19·0 to 22·0) –5·00 (–32·1 to 29·7) –14·6 (–24·8 to –4·31)
Honduras 5·25 (4·15 to 6·61) 24·0 (22·2 to 25·9) –11·8 (–35·3 to 16·4) –19·9 (–28·4 to –10·5)
Mexico 9·01 (7·79 to 10·3) 27·0 (25·7 to 28·2) –48·1 (–57·1 to –38·3) –40·6 (–44·3 to –36·8)
Nicaragua 5·46 (4·15 to 7·01) 21·5 (19·5 to 23·7) –16·2 (–42·4 to 17·4) –23·3 (–33·2 to –12·7)
Panama 4·57 (3·58 to 5·71) 12·4 (11·3 to 13·7) –35·9 (–54·5 to –10·6) –39·1 (–46·3 to –31·1)
Venezuela 11·7 (9·37 to 14·5) 22·8 (20·5 to 25·2) –32·2 (–49·8 to –11·0) –35·3 (–42·6 to –27·0)
Tropical Latin America 6·90 (6·06 to 7·74) 11·2 (10·6 to 11·9) –74·3 (–77·6 to –70·8) –71·5 (–73·7 to –69·2)
Brazil 6·86 (6·02 to 7·73) 10·9 (10·1 to 11·6) –74·7 (–78·0 to –71·2) –72·5 (–74·7 to –70·1)
Paraguay 8·33 (6·79 to 10·1) 24·6 (22·7 to 26·7) –41·9 (–56·4 to –24·7) –39·7 (–46·3 to –33·4)
North Africa and Middle East 5·63 (5·31 to 5·99) 32·4 (31·9 to 32·9) –2·88 (–12·7 to 7·23) –11·2 (–13·6 to –8·75)
Afghanistan 2·67 (2·10 to 3·39) 17·0 (15·7 to 18·4) 179 (93·4 to 285) 205 (158 to 254)
Algeria 1·74 (1·34 to 2·24) 32·7 (30·6 to 34·8) –28·7 (–51·5 to –0·699) –7·01 (–16·2 to 2·31)
Bahrain 5·10 (4·13 to 6·33) 23·4 (21·4 to 25·5) –20·7 (–40·4 to 2·68) –1·03 (–11·1 to 10·0)
Egypt 1·06 (0·803 to 1·37) 43·4 (42·2 to 44·7) 2·41 (–31·7 to 50·5) 13·1 (4·88 to 21·9)
Iran 4·73 (3·84 to 5·75) 24·9 (23·2 to 26·5) 8·28 (–26·7 to 47·9) 2·30 (–8·74 to 14·6)
Iraq 3·53 (2·81 to 4·38) 37·6 (35·4 to 39·6) –22·1 (–45·0 to 6·51) –18·8 (–25·2 to –11·5)
Jordan 11·8 (10·1 to 13·8) 53·0 (51·5 to 54·5) 10·6 (–15·8 to 44·6) 11·4 (4·64 to 18·3)
Kuwait 4·72 (3·78 to 5·76) 33·7 (31·5 to 35·8) –8·57 (–36·3 to 24·3) –14·2 (–21·6 to –6·18)
Lebanon 26·0 (22·8 to 29·0) 46·1 (44·0 to 48·2) 45·1 (15·8 to 80·2) 25·1 (14·4 to 36·5)
Libya 1·46 (1·10 to 1·94) 38·6 (36·3 to 41·0) –2·10 (–34·2 to 38·4) 0·602 (–8·37 to 10·7)
Morocco 1·06 (0·788 to 1·42) 22·5 (20·9 to 24·1) –31·3 (–54·3 to 1·02) –33·2 (–39·3 to –26·1)
Oman 1·88 (1·45 to 2·43) 15·8 (14·5 to 17·3) –11·0 (–37·4 to 23·1) –24·6 (–32·4 to –16·5)
Palestine 3·89 (3·07 to 4·84) 40·8 (38·6 to 43·2) –3·23 (–29·4 to 28·9) –8·48 (–14·7 to –2·05)
Qatar 2·97 (2·24 to 3·94) 21·9 (20·3 to 23·6) 4·14 (–32·9 to 54·7) –4·13 (–15·4 to 8·50)
Saudi Arabia 2·17 (1·69 to 2·71) 22·6 (21·1 to 24·0) 45·3 (0·241 to 99·6) 39·0 (26·2 to 53·6)
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Sudan 1·95 (1·46 to 2·54) 19·5 (18·0 to 21·1) –15·2 (–42·5 to 23·4) –12·3 (–22·9 to –0·539)
Syria 6·20 (4·77 to 7·97) 41·9 (39·0 to 44·8) –23·3 (–47·1 to 6·07) –16·5 (–23·3 to –9·84)
Tunisia 2·70 (2·12 to 3·45) 45·4 (43·2 to 47·7) –19·9 (–43·5 to 10·8) –11·1 (–17·0 to –4·99)
Turkey 18·4 (16·6 to 20·3) 43·2 (41·6 to 44·9) 14·6 (–3·48 to 33·5) –21·8 (–26·3 to –17·2)
United Arab Emirates 3·79 (2·96 to 4·81) 17·9 (16·5 to 19·3) 2·58 (–27·0 to 44·1) –21·0 (–30·5 to –10·8)
Yemen 8·90 (7·46 to 10·7) 31·5 (29·5 to 33·6) 4·41 (–24·0 to 40·2) –4·64 (–14·1 to 5·27)
South Asia 3·26 (2·83 to 3·78) 25·2 (24·2 to 26·2) –34·1 (–45·8 to –21·1) –37·8 (–40·4 to –35·1)
Bangladesh 2·13 (1·68 to 2·66) 44·9 (43·0 to 47·0) –27·9 (–47·7 to –4·36) –11·4 (–16·7 to –6·25)
Bhutan 4·80 (3·79 to 5·95) 14·8 (13·4 to 16·2) –4·62 (–33·8 to 31·6) –12·9 (–24·1 to –0·228)
India 3·10 (2·59 to 3·74) 23·0 (21·9 to 24·2) –31·2 (–46·6 to –12·9) –41·0 (–44·2 to –37·6)
Nepal 13·6 (11·9 to 15·6) 31·4 (29·8 to 33·0) –54·0 (–61·9 to –44·6) –37·0 (–41·4 to –32·6)
Pakistan 3·77 (3·05 to 4·65) 24·7 (23·3 to 26·3) –40·7 (–58·0 to –18·0) –39·2 (–44·3 to –33·6)
Southeast Asia, east Asia, 
and Oceania
3·94 (3·51 to 4·39) 49·4 (48·4 to 50·4) –22·1 (–33·2 to –11·0) –16·6 (–18·6 to –14·5)
East Asia 3·57 (2·97 to 4·18) 49·5 (48·0 to 50·8) –20·7 (–36·4 to –3·84) –18·1 (–20·8 to –15·4)
China 3·54 (2·91 to 4·18) 49·7 (48·3 to 51·1) –20·9 (–37·4 to –3·53) –18·2 (–21·0 to –15·5)
North Korea 4·48 (3·57 to 5·69) 43·6 (41·3 to 45·6) 11·6 (–20·7 to 51·2) –8·47 (–15·3 to –0·989)
Taiwan (Province of China) 4·98 (3·94 to 6·21) 39·6 (37·5 to 41·7) –27·9 (–51·0 to –0·968) –18·2 (–24·3 to –11·5)
Oceania 18·0 (16·0 to 20·2) 41·3 (39·4 to 43·2) –17·7 (–32·1 to –1·23) –14·9 (–19·7 to –9·54)
American Samoa 22·4 (18·3 to 27·2) 42·1 (39·2 to 45·2) –4·19 (–27·7 to 25·2) –4·14 (–12·7 to 5·48)
Cook Islands 24·2 (20·5 to 28·6) 36·7 (34·4 to 39·1) –0·774 (–21·8 to 25·9) –9·81 (–18·7 to –0·276)
Federated States of Micronesia 36·4 (31·0 to 41·5) 62·2 (59·7 to 64·8) 12·4 (–9·52 to 35·5) 3·73 (–2·38 to 9·83)
Fiji 14·5 (12·0 to 17·3) 42·5 (40·0 to 45·4) –18·9 (–38·4 to 6·27) –14·8 (–21·6 to –7·97)
Guam 20·1 (17·8 to 22·3) 30·3 (28·6 to 32·1) –8·28 (–26·4 to 12·2) –14·6 (–22·4 to –6·08)
Kiribati 35·1 (31·5 to 38·6) 63·8 (61·7 to 65·9) 0·681 (–16·7 to 21·3) 6·98 (0·976 to 13·2)
Marshall Islands 9·75 (7·74 to 12·0) 35·0 (32·3 to 37·5) 27·1 (–9·19 to 75·7) 3·09 (–7·84 to 15·3)
Nauru 40·3 (36·3 to 44·6) 43·3 (40·9 to 45·8) –7·17 (–22·1 to 9·84) –4·09 (–11·8 to 4·43)
Niue 15·8 (13·1 to 18·8) 27·0 (25·0 to 29·1) –1·31 (–26·2 to 32·3) –7·53 (–17·6 to 3·99)
Northern Mariana Islands 18·0 (14·3 to 22·1) 41·0 (38·0 to 43·9) –17·7 (–37·6 to 8·84) –13·1 (–21·1 to –4·45)
Palau 12·6 (10·9 to 14·5) 32·4 (30·6 to 34·3) –1·96 (–25·5 to 25·2) –6·71 (–15·4 to 3·12)
Papua New Guinea 18·4 (15·8 to 21·3) 40·2 (37·7 to 42·6) –21·2 (–38·7 to 0·844) –17·3 (–23·9 to –10·2)
Samoa 14·5 (12·5 to 16·6) 39·4 (37·2 to 41·6) –11·6 (–32·5 to 13·1) –11·4 (–18·4 to –4·35)
Solomon Islands 19·3 (17·0 to 21·8) 52·2 (49·9 to 54·2) 7·00 (–16·4 to 36·0) 3·90 (–2·92 to 11·7)
Tokelau 16·6 (13·0 to 20·6) 39·6 (36·4 to 42·5) 0·116 (–26·1 to 31·5) –5·30 (–14·4 to 5·05)
Tonga 13·3 (11·3 to 15·4) 42·5 (40·2 to 44·8) –1·21 (–20·6 to 22·1) –22·3 (–27·0 to –17·2)
Tuvalu 20·7 (17·3 to 24·4) 45·4 (42·6 to 48·0) 9·73 (–17·7 to 43·3) 3·49 (–4·63 to 13·0)
Vanuatu 5·70 (4·54 to 6·95) 38·2 (36·0 to 40·3) –17·8 (–43·4 to 14·2) –11·8 (–19·4 to –3·90)
Southeast Asia 4·51 (4·18 to 4·87) 48·2 (47·5 to 48·9) –29·9 (–37·0 to –22·0) –12·6 (–14·4 to –10·7)
Cambodia 5·09 (4·17 to 6·10) 40·6 (38·8 to 42·3) –13·9 (–34·6 to 10·6) –19·7 (–24·3 to –14·7)
Indonesia 3·60 (3·00 to 4·31) 58·3 (57·0 to 59·6) 7·99 (–17·2 to 39·2) 6·94 (3·14 to 10·6)
Laos 6·98 (5·73 to 8·29) 49·1 (46·8 to 51·2) 29·3 (–6·25 to 71·2) 9·06 (1·05 to 17·2)
Malaysia 3·20 (2·57 to 3·92) 40·3 (38·1 to 42·3) –26·0 (–47·5 to 1·04) –22·3 (–28·1 to –16·0)
Maldives 7·35 (5·88 to 9·03) 46·5 (43·8 to 48·9) –6·48 (–32·8 to 23·8) –6·02 (–13·3 to 0·792)
Mauritius 5·40 (4·36 to 6·60) 41·2 (39·2 to 43·3) –7·65 (–32·1 to 23·3) –13·0 (–19·2 to –6·93)
Myanmar 8·59 (7·24 to 10·0) 41·0 (39·2 to 42·8) –48·7 (–59·6 to –35·3) –32·2 (–36·6 to –27·8)
Philippines 8·24 (7·24 to 9·31) 40·9 (39·3 to 42·5) –37·7 (–50·7 to –22·6) –28·9 (–32·9 to –24·6)
Seychelles 7·01 (5·58 to 8·62) 39·7 (36·9 to 42·4) –5·93 (–34·0 to 30·1) –10·9 (–19·7 to –1·99)
Sri Lanka 1·80 (1·39 to 2·26) 30·1 (28·5 to 31·8) –40·7 (–58·4 to –17·4) –30·8 (–36·0 to –24·9)
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Age-standardised prevalence, 2019 Percentage change 1990–2019
Females Males Females Males
(Continued from previous page)
Thailand 3·49 (2·89 to 4·19) 39·8 (38·5 to 41·3) –46·5 (–59·9 to –31·5) –25·5 (–29·4 to –21·5)
Timor-Leste 5·15 (4·18 to 6·21) 64·6 (62·7 to 66·6) –4·15 (–30·1 to 26·9) 1·49 (–3·55 to 6·71)
Vietnam 2·68 (2·13 to 3·30) 47·1 (45·3 to 48·8) –32·9 (–50·2 to –13·4) –20·3 (–24·2 to –16·3)
Sub-Saharan Africa 2·94 (2·78 to 3·10) 17·5 (17·2 to 17·9) –34·1 (–39·1 to –28·9) –22·8 (–24·7 to –20·6)
Central sub-Saharan Africa 1·74 (1·46 to 2·06) 20·7 (19·6 to 22·0) –4·72 (–26·1 to 18·9) –6·47 (–14·6 to 1·85)
Angola 2·74 (2·14 to 3·51) 18·7 (17·2 to 20·2) –9·87 (–36·6 to 23·5) –13·2 (–23·3 to –1·61)
Central African Republic 1·60 (1·22 to 2·12) 15·0 (13·3 to 16·8) –26·1 (–50·2 to 4·37) –25·8 (–36·0 to –15·1)
Congo (Brazzaville) 1·81 (1·33 to 2·42) 20·7 (19·0 to 22·6) 20·3 (–24·1 to 75·6) 28·8 (13·7 to 47·7)
Democratic Republic of 
the Congo
1·36 (1·01 to 1·79) 21·6 (20·0 to 23·4) –6·49 (–38·2 to 34·9) –5·93 (–17·1 to 5·72)
Equatorial Guinea 2·50 (1·81 to 3·47) 27·5 (25·0 to 29·8) 4·27 (–36·2 to 58·2) 1·93 (–10·7 to 15·7)
Gabon 3·55 (2·71 to 4·54) 21·9 (20·3 to 23·7) 26·1 (–17·1 to 84·3) 17·3 (1·42 to 35·2)
Eastern sub-Saharan Africa 3·14 (2·93 to 3·37) 17·6 (17·1 to 18·0) –18·6 (–26·5 to –9·69) –23·7 (–26·4 to –20·4)
Burundi 4·23 (3·38 to 5·28) 16·3 (15·1 to 17·5) –31·9 (–52·9 to –4·28) –36·3 (–43·5 to –28·5)
Comoros 2·99 (2·31 to 3·76) 23·3 (21·5 to 25·1) –6·26 (–35·1 to 35·3) –15·6 (–25·0 to –5·67)
Djibouti 5·52 (4·36 to 6·90) 42·2 (39·6 to 44·9) 14·4 (–18·8 to 61·1) 15·9 (5·62 to 27·6)
Eritrea 0·696 (0·517 to 0·906) 12·5 (11·2 to 13·9) –20·8 (–48·8 to 13·5) –21·9 (–33·4 to –8·83)
Ethiopia 1·31 (1·01 to 1·69) 10·5 (9·60 to 11·4) –3·30 (–33·3 to 37·1) –15·5 (–26·7 to –2·48)
Kenya 2·52 (2·00 to 3·20) 19·2 (17·8 to 20·4) –35·2 (–54·4 to –9·94) –35·8 (–42·2 to –28·8)
Madagascar 2·57 (2·00 to 3·30) 24·9 (22·9 to 26·8) –40·1 (–57·7 to –16·5) –37·7 (–44·0 to –30·9)
Malawi 3·11 (2·44 to 3·93) 24·0 (22·6 to 25·4) –15·5 (–41·7 to 17·6) –0·233 (–9·99 to 10·1)
Mozambique 5·94 (4·68 to 7·39) 23·6 (21·6 to 25·7) –7·30 (–34·1 to 27·9) –5·52 (–17·2 to 6·57)
Rwanda 8·51 (7·00 to 10·1) 21·7 (20·4 to 23·2) –1·82 (–26·1 to 29·3) –1·51 (–12·1 to 10·9)
Somalia 2·82 (2·17 to 3·66) 20·5 (18·3 to 22·7) –17·9 (–43·1 to 12·0) –15·7 (–26·9 to –4·18)
South Sudan 2·71 (2·05 to 3·43) 20·6 (18·5 to 22·8) –18·4 (–42·3 to 9·34) –17·7 (–28·2 to –7·07)
Uganda 4·18 (3·43 to 5·02) 14·6 (13·6 to 15·6) –1·00 (–26·2 to 31·2) –24·0 (–32·4 to –15·0)
Tanzania 2·96 (2·35 to 3·68) 18·0 (16·8 to 19·2) –27·7 (–49·0 to –1·96) –38·9 (–45·2 to –31·8)
Zambia 5·82 (4·75 to 6·99) 26·3 (24·9 to 27·7) –10·0 (–32·5 to 18·6) 4·43 (–5·87 to 16·0)
Southern sub-Saharan Africa 8·70 (7·51 to 10·0) 34·6 (33·3 to 35·7) –36·8 (–47·8 to –25·7) –22·7 (–26·0 to –18·9)
Botswana 8·39 (7·02 to 9·77) 36·3 (34·4 to 38·2) –19·1 (–38·0 to 7·26) –6·48 (–14·6 to 1·90)
eSwatini 2·87 (2·28 to 3·67) 15·0 (13·6 to 16·5) –26·9 (–47·4 to –0·171) –30·9 (–38·9 to –21·5)
Lesotho 1·85 (1·42 to 2·42) 41·5 (39·6 to 43·5) 4·41 (–27·9 to 50·9) 29·5 (17·1 to 42·3)
Namibia 10·6 (8·83 to 12·7) 23·5 (21·9 to 25·1) –25·7 (–43·6 to –5·01) –21·6 (–29·4 to –13·3)
South Africa 10·4 (8·75 to 12·2) 35·4 (33·8 to 36·9) –38·0 (–50·2 to –24·8) –27·5 (–31·3 to –23·3)
Zimbabwe 3·47 (2·73 to 4·29) 34·4 (32·6 to 36·0) –8·90 (–35·9 to 24·1) 3·59 (–5·33 to 13·2)
Western sub-Saharan Africa 1·81 (1·64 to 2·02) 12·7 (12·2 to 13·1) –33·7 (–42·9 to –23·7) –23·0 (–26·9 to –18·9)
Benin 1·69 (1·28 to 2·15) 10·6 (9·77 to 11·5) –45·1 (–63·0 to –23·6) –42·3 (–49·6 to –34·4)
Burkina Faso 1·47 (1·10 to 1·93) 17·0 (15·7 to 18·4) –32·4 (–55·1 to –1·13) –28·2 (–36·7 to –18·4)
Cameroon 1·51 (1·14 to 1·94) 14·8 (13·5 to 16·2) –24·1 (–47·2 to 6·20) –33·9 (–42·5 to –24·7)
Cape Verde 3·00 (2·36 to 3·83) 9·39 (8·41 to 10·5) –35·2 (–54·4 to –9·63) –45·5 (–53·3 to –36·9)
Chad 2·83 (2·23 to 3·63) 16·0 (14·7 to 17·4) –33·7 (–54·0 to –7·61) –30·4 (–38·9 to –20·5)
Côte d’Ivoire 3·79 (2·89 to 4·83) 21·8 (20·0 to 23·7) 0·960 (–28·8 to 37·6) 10·9 (–3·13 to 26·9)
The Gambia 1·33 (1·02 to 1·72) 23·6 (21·9 to 25·3) –35·0 (–55·2 to –9·14) –32·4 (–39·2 to –25·1)
Ghana 2·08 (1·58 to 2·72) 10·5 (9·42 to 11·6) 6·37 (–26·7 to 56·4) –7·41 (–20·7 to 7·27)
Guinea 2·03 (1·54 to 2·56) 29·2 (26·6 to 31·9) –5·65 (–34·9 to 30·1) –8·87 (–19·3 to 2·07)
Guinea-Bissau 1·07 (0·811 to 1·39) 8·46 (7·42 to 9·54) 3·39 (–29·1 to 46·7) 16·3 (–2·20 to 38·5)
Liberia 2·57 (2·03 to 3·24) 13·7 (12·5 to 15·0) 1·62 (–30·8 to 43·3) –12·8 (–24·2 to 0·646)
Mali 2·44 (1·83 to 3·22) 22·5 (20·8 to 24·1) 47·6 (–2·39 to 113) 27·0 (12·4 to 44·0)
Mauritania 8·08 (6·28 to 10·1) 29·3 (26·8 to 31·8) –12·3 (–39·3 to 20·6) –21·6 (–29·5 to –11·8)
Niger 1·63 (1·23 to 2·16) 14·1 (12·8 to 15·6) 18·3 (–21·9 to 68·9) 12·0 (–5·17 to 30·8)
(Table continues on next page)
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increased significantly over the past 30 years in 
20 countries for males (Afghanistan, Saudi Arabia, 
Uzbekistan, El Salvador, Antigua and Barbuda, Lesotho, 
Congo [Brazzaville], Mali, Albania, Lebanon, São Tomé 
and Príncipe, Bosnia and Herzegovina, Gabon, Djibouti, 
Egypt, Jordan, Mongolia, Laos, Kiribati, and Indonesia) 
and in 12 countries for females (Afghanistan, Albania, 
Kyrgyzstan, Saudi Arabia, Lebanon, Mongolia, Bosnia 
and Herzegovina, Belarus, Portugal, Lithuania, Russia, 
and Serbia; table). Across both sexes combined, the 
largest decreases in age-standardised prevalence of 
smoking tobacco use were observed in Brazil (73·4% 
[71·4–75·2]), Norway (53·5% [49·1–57·6]), Senegal 
(50·9% [44·6–56·0]), Iceland (49·7% [44·5–54·1]), 
Denmark (49·3% [46·4–52·2]), Haiti (47·5% [40·5–54·4]), 
Australia (47·5% [43·1–51·8]), Costa Rica (47·4% 
[40·5–53·6]), Canada (47·4% [42·4–52·0]), and Colombia 
(47·1% [40·4–53·4]; appendix 2 pp 94–102).
Analysing the annualised rate of change per 5-year 
period in individuals aged 15 years and older between 
1990 and 2019, we found the largest number of countries 
had their fastest decrease in age-standardised prevalence 
of smoking tobacco use between 2005 and 2009 for both 
males (68 countries) and females (56 countries; figure 1; 
country-level data are available online through the 
GHDx). Overall, 115 (56%) of 204 countries for males 
and 136 (67%) countries for females had their fastest 
decrease after the FCTC was ratified (ie, after 2005). 
Notably, decreases in prevalence were smaller in the 
period 2015–19 than in the period 2010–15 in 
Age-standardised prevalence, 2019 Percentage change 1990–2019
Females Males Females Males
(Continued from previous page)
Nigeria 1·16 (0·862 to 1·54) 7·43 (6·69 to 8·21) –53·3 (–67·9 to –33·2) –38·5 (–46·7 to –30·1)
São Tomé and Príncipe 1·70 (1·29 to 2·22) 7·80 (6·95 to 8·69) 15·1 (–23·8 to 70·5) 24·2 (5·43 to 43·3)
Senegal 1·46 (1·11 to 1·90) 14·2 (13·2 to 15·3) –41·2 (–60·4 to –17·5) –52·3 (–57·5 to –46·0)
Sierra Leone 7·84 (6·34 to 9·61) 30·5 (28·7 to 32·6) –26·1 (–46·8 to 0·307) –13·1 (–21·4 to –3·07)
Togo 2·26 (1·73 to 2·92) 14·0 (12·8 to 15·2) –37·3 (–57·5 to –11·9) –42·8 (–49·8 to –35·5)
Data are given to three significant figures. Data in parentheses are 95% uncertainty intervals.
Table: Age-standardised prevalence of current smoking tobacco use in 2019 and percentage change in age-standardised prevalence of current smoking 
tobacco use in 1990–2019 among individuals aged 15 years and older, by location and sex
Figure 1: Annualised rate of change in number of tobacco smokers (A) and age-standardised prevalence of smoking tobacco use (B), by super-region
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152 (75%) countries for males and 137 (67%) countries 
for females (figure 1; country-level data are available 
online through the GHDx).
In many countries, reductions in prevalence have not 
kept pace with population growth (figure 1; appendix 2 
pp 94–102). As a result, the number of smokers globally 
has increased steadily each year since 1990, when there 
were 0·99 billion (95% UI 0·98–1·00) smokers globally, 
with the exception of the period between 2011 and 2017, 
during which no significant change in the number 
of smokers occurred (figure 1). Of 204 countries and 
territories included in our analysis, 113 (55%) had a 
significant increase in the number of current smokers 
between 1990 and 2019 and 111 (54%) had a significant 
increase between 2005 and 2019. Among both males and 
females, the super-regions with the largest relative 
increases in the number of smokers since 1990 were 
north Africa and the Middle East (104·1% [98·1–111] 
increase) and sub-Saharan Africa (74·6% [69·9–79·1] 
increase; appendix 2 pp 94–102). The largest relative 
decreases in the number of smokers were observed in 
the Latin America and the Caribbean (19·8% [16·9–22·5] 
decrease) and high-income (17·6% [16·2–18·9] decrease) 
super-regions.
7·41 trillion (95% UI 7·11–7·74) cigarette-equivalents of 
tobacco were consumed in 2019, amounting to 20·3 billion 
(19·5–21·2) cigarette-equivalents consumed each day 
worldwide. China accounted for more than a third of the 
world’s tobacco consumption (2·72 trillion [2·47–3·01] 
cigarette-equivalents). Countries with the highest con-
sump tion per person in 2019 were mostly in Europe, with 
Montenegro, North Macedonia, Bulgaria, Slovenia, and 
Greece all having consumption exceeding 2350 cigarette-
equivalents per person (appendix 2 pp 103–111). Countries 
with the lowest consumption per person were mostly in 
sub-Saharan Africa (appendix 2 pp 103–110).
Cigarettes smoked per day is an important predictor of 
disease risk, although smokers who consume only a few 
cigarettes each day still have considerable excess risk 
compared with non-smokers. Among 719 million male 
current smokers aged 30 years and older in 2019, 
83·2 million (11·6%) smoked 1–4 cigarette-equivalents 
per day, 139·2 million (19·4%) smoked 5–9 cigarette-
equivalents per day, 144·0 mil lion (20·0%) smoked 
10–14 cigarette-equivalents per day, 120·5 million (16·8%) 
smoked 15–19 cigarette-equivalents per day, and 
231·9 million (32·3%) smoked 20 or more cigarette-
equivalents per day (figure 2). Among 146 million female 
current smokers aged 30 years and older in 2019, 
27·0 million (18·5%) smoked 1–4 cigarette-equivalents 
per day, 39·0 million (26·7%) smoke 5–9 cigarette-
equivalents per day, 32·4 million (22·1%) smoked 
10–14 cigarette-equivalents per day, 20·8 million (14·2%) 
smoked 15–19 cigarette-equivalents per day, and 
27·1 million (18·5%) smoked 20 or more cigarette-
equivalents per day (figure 2). The distribution of 
cigarette-equivalents per smoker per day varies across 
countries. Most of the male current smoker population 
aged 30 years and older in 72 countries and most of the 
female current smoker population in 121 countries smoke 
fewer than 10 cigarette-equivalents per day on average 
(data not shown).
In 2019, 7·69 million (95% UI 7·16–8·20) deaths 
and 200 million (185–214) DALYs were attributable to 
Figure 2: Distribution of number of tobacco smokers aged 30 years and older, by cigarette-equivalents smoked per day (A), and pack-years among current 
smokers (B), and years since quitting among former smokers (C), by sex and geographical region in 2019
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smoking tobacco use, accounting for 13·6% (13·0–14·3) 
of all deaths and 7·89% (7·19–8·56) of all DALYs 
(appendix 2 pp 112–165). 6·18 million (80%) of these 
deaths were among males, and smoking accounted for 
the largest number and proportion (20·2% [19·3–21·1]) 
of deaths among males of the 87 risk factors included 
in GBD 2019.1 Among females, smoking accounted for 
1·51 million (1·40–1·63) deaths and 5·84% (5·47–6·22) 
of all deaths. YLLs due to smoking tobacco use, which 
quantify the effects of premature mortality, exceeded 
YLDs due to smoking in 2019, which quantify the effects 
of non-fatal health loss, (168 million [156–180] YLLs vs 
31·6 million [23·7–40·0] YLDs). The ratio of YLLs to 
YLDs attributable to smoking tobacco use varied 
across countries, from 1·59 (1·03–2·44) in Qatar 
to 16·1 (11·2–22·7) in the Solomon Islands (appendix 2 
pp 166–174). Ratios of YLLs to YLDs decreased with 
increasing Socio-demographic Index level (appendix 2 
p 175). Lower ratios of YLLs to YLDs indicate that a greater 
proportion of individuals are living with chronic health 
conditions due to smoking tobacco use in these countries 
than in countries with higher ratios of YLLs to YLDs.
Of the 36 health outcomes caused by smoking tobacco 
use (appendix 2 pp 5–82), the health outcomes with the 
largest number of deaths attributable to smoking tobacco 
use for both sexes combined in 2019 were ischaemic 
heart disease (1·68 million [95% UI 1·56–1·81]); chronic 
obstructive pulmonary disease (1·59 million [1·41–1·76]); 
tracheal, bronchus, and lung cancer (1·31 million 
[1·20–1·43]); and stroke (0·931 million [0·833–1·00]; 
appendix 2 pp 176–177), which together accounted for 
approxi mately 72% of all deaths attributable to smoking 
tobacco use that year. Top causes of death attributable 
to smoking varied by region, reflecting differences in 
both background cause-specific death rates and patterns 
of smoking. Ischaemic heart disease was the leading 
cause of deaths attributable to smoking tobacco use in all 
super-regions except the high-income super-region, for 
which the leading cause was lung cancer, and for 
countries in the southeast Asia, east Asia, and Oceania 
super-region for which the leading cause was chronic 
obstructive pulmonary disease (appendix 2 pp 176–177).
An estimated 5·96 million (77·5%) of 7·69 million 
deaths attributable to smoking tobacco use occurred 
in low-income and middle-income countries in 2019. 
Ukraine had the highest death rate from smoking 
among males (487 per 100 000 males [95% UI 396–590; 
appendix 2 pp 112–138). Countries with high rates of 
deaths attrib utable to smoking tobacco use among males 
were predominantly in the central Europe, eastern Europe, 
and east Asia regions. Among females, four locations had 
rates of deaths attributable to smoking tobacco use higher 
than 180 per 100 000 females (Denmark, Montenegro, 
Serbia, and Greenland; appendix 2 pp 112–138).
Across all age groups, smoking tobacco use was the 
cause of more than 20% of all male deaths in 73 countries 
in 2019 (figure 3). 43 (59%) of 73 countries were 
designated as low-income or middle-income countries. 
Among all females, smoking accounted for more 
than 20% of deaths in only two locations (Denmark and 
Greenland), due to both lower smoking prevalence, 
shorter duration of smoking, and lower smoking 
intensity among females than among males (figure 3). 
The proportion of deaths attributable to smoking tobacco 
use increased with age, peaking among those aged 
60–64 years (22·0% [95% UI 21·1–23·1] of deaths 
attributable to smoking), before decreasing in older age 
groups (appendix 2 p 178).
The share of all-cause deaths that were due to 
smoking tobacco use decreased significantly between 
1990 and 2019 in 68 countries, increased significantly 
in 71 countries, and stayed constant in 65 countries 
(appendix 2 pp 179–187). 66 (93%) of 71 countries with 
significant increases in the proportion of all-cause deaths 
attributable to smoking tobacco use were low-income 
and middle-income countries. The largest decreases 
were observed in Australia, New Zealand, South Africa, 
Singapore, and Norway, whereas the largest increases 
were observed in Timor-Leste, Bhutan, Niger, São Tomé 
and Príncipe, and Malawi (appendix 2 pp 179–187). The 
largest absolute increases in the number of deaths 
attributable to tobacco smoking between 1990 and 2019 
were observed in China (from 1·5 million deaths in 1990 
to 2·4 million in 2019; a 57·9% [26·2–101] increase), 
India (from 0·6 million deaths in 1990 to 1·0 million 
in 2019; a 58·9% [30·7–90·8] increase), and Indonesia 
(from 112 800 deaths in 1990 to 246 400 deaths in 2019; 
a 118% [74·0–171] increase; appendix 2 pp 179–187).
The dose-response association between risk exposure 
and disease results in an uneven distribution of burden 
among the current and former smoking populations 
aged 30 years and older (figure 4). Among ever smokers 
aged 30 years and older, 865 mil lion (65·9%) of 1·31 billion 
are current smokers and 449 million (34·1%) are former 
smokers. A dis proportionate share of all deaths attri-
butable to smoking tobacco use occurred among current 
smokers (6·68 million [86·9%] of 7·69 million). Among 
former smokers, health risks decreased as a function of 
years since cessation (figure 4). Only 0·467 million (6·18%) 
global deaths attributable to smoking tobacco use 
occurred among individuals who had quit smoking at 
least 15 years ago, despite this group accounting for 
257 million (19·6%) members of the global ever smoker 
population.
Discussion
In this study, we present updated results on the 
prevalence of smoking tobacco use and the attributable 
disease burden from GBD 2019. We used new direct 
estimation methods, which allowed more compre-
hensive estimations, including reflecting dose-response 
associations between exposure and risk of disease and 
capture of health effects among daily and occasional 
smokers and former smokers. By using continuous 
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Figure 3: Proportion of all-cause deaths that were attributable to smoking tobacco use among females (A) and males (B) of all ages in 2019
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exposure measures, we are better able to capture 
differences in risk across countries that result from 
heterogenous smoking patterns. Our findings are an 
urgent call to action for countries to implement and 
enforce stronger tobacco control policies than are 
currently in place, and serve as a blue print for targeting 
interventions, monitoring progress, allocating resources, 
and planning for future health system strain.
In 2019, more than 1 billion people smoked tobacco 
regularly, and almost 8 million deaths were attributable 
to smoking. Smoking tobacco use accounted for 
20·2% of all-cause deaths among males, and was the 
leading risk factor for both deaths and DALYs among 
males. Among females, smoking tobacco use accounted 
for approximately 5·8% of all deaths, due to lower 
prevalence, shorter duration, and lower intensity of 
smoking than in males. Tobacco control has contributed 
to reductions in global prevalence of smoking tobacco 
use of 27·5% (95% UI 26·5–28·5) for males and 
37·7% (35·4–39·9) for females. However, these global 
aggregates do not illustrate important between-country 
heterogeneity. Between 1990 and 2019, significant 
decreases in prevalence of smoking tobacco use were 
observed in 135 countries for males and 68 countries for 
females, while significant increases were observed in 
20 countries for males and 12 countries for females.
Although tobacco control efforts began as early as in 
the 1960s in some countries after the detrimental health 
effects of tobacco smoking were first documented, global 
progress in tobacco control was catalysed with the 
passing of the WHO FCTC in 2005.9,33 The decade 
following the introduction of the WHO FCTC was the 
period of fastest decrease in the prevalence of smoking 
tobacco use across the largest number of countries.34 
The effectiveness of the demand-reduction policies 
outlined in the FCTC articles has been documented, and 
the large reductions in prevalence of smoking tobacco 
use between 1990 and 2019 were observed in Brazil 
(73·4% decrease), Norway (53·5% decrease), and Senegal 
(50·9% decrease), along with Iceland, Denmark, Canada, 
Australia, Colombia, and Costa Rica, all with decreases in 
prevalence exceeding 45%, show the potential of these 
tools to operate in diverse contexts to greatly reduce the 
prevalence of smoking tobacco use and save millions of 
lives over the coming decades.35–38
Despite these successes, we observed three concerning 
patterns. First, in several countries with large populations 
and high prevalence of smoking tobacco use, including 
China (2·4 million deaths in 2019, a 57·9% [95% UI 
26·2–101] increase in attributable deaths since 1990) and 
Indonesia (246 400 deaths in 2019, a 118% [74·0–171] 
increase in attributable deaths since 1990), little to no 
progress has been made in reducing the prevalence of 
smoking. Second, most countries did not have sufficient 
decreases in the prevalence of smoking to offset the 
demographic force of population growth, resulting in 
constant or increasing numbers of smokers over time. 
And third, in many countries, including those that had 
large decreases in prevalence previously, the rate of 
progress has slowed, particularly in the past 5 years.
113 of 204 countries had a significant increase in the 
number of smokers since 1990, and 111 countries 
had a significant increase since 2005. To achieve the 
goals set forth in the SDGs and WHO global non-
communicable disease monitoring framework, and in 
doing so reclaim the 200 million DALYs lost to smoking 
tobacco use each year, most countries will need 
Figure 4: Number of deaths from cancers and chronic obstructive pulmonary disease (A) and deaths from 
cardiovascular and circulatory diseases and all other health outcomes (excluding cancers and chronic 
obstructive pulmonary disease; B) attributable to smoking tobacco use in individuals aged 30 years and 
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stronger tobacco control policies than those already in 
place. As of 2018, only 62 countries had comprehensive 
smoke-free policies; 23 offered the full range of 
cessation support services recommended by WHO; 
91 mandated best-practice pictorial health warnings; 
48 were protected by complete advertising, promotion, 
and sponsorship bans; and 38 had the recommended 
level of tobacco taxation.10 Closing gaps in the adoption, 
implemen tation, and enforcement of evidence-based 
demand-reduction policies is vital to ending the global 
tobacco epidemic.
Taxation is one of the most effective tobacco control 
policies available to countries.4 Increasing taxes decreases 
demand by reducing the affordability of tobacco products. 
As income and purchasing power increase, particularly in 
rapidly developing countries, concordant increases in 
tobacco taxes to reduce affordability are necessary for this 
fiscal policy to remain potent. Yet, between 2008 and 2018, 
the affordability of cigarettes decreased in only 33% of low-
income countries compared with in 38% of middle-income 
countries and 72% of high-income countries.10 Only one 
low-income country, Madagascar, taxes tobacco at the rate 
recommended by the WHO MPOWER framework. Low-
income and middle-income countries face the additional 
challenge of population growth expanding their smoking 
population. Tobacco taxation is a highly cost-effective 
measure, and when combined with a progressive approach 
to redistributing revenue from taxation to tobacco control 
programmes, health care, and other social support 
services, can greatly reduce the prevalence of smoking and 
substantially improve population health.39
With 1·14 billion current smokers globally in 2019, 
increasing cessation rates among current smokers can 
yield massive health gains. We estimated that fewer 
than 15% of deaths attributable to smoking tobacco use 
in 2019 occurred among former smokers aged 30 years 
and older, despite former smokers comprising approxi-
mately a third of the ever smoker population aged 
30 years and older. Consistent with other studies, we 
found in our meta-analyses of risk reduction among 
former smokers that cessation shifts smokers into a 
lower-risk category, with greater reduction in risk for 
longer durations since cessation.40–42 Relative risks of 
all-cause mortality from long-running cohort studies in 
the UK41,42 and the USA43 indicate that up to two-thirds 
of long-term smokers will eventually die of a disease 
attributable to smoking. These data underscore the 
importance of adopting policies and interventions that 
increase rates of cessation.
The results of our study must be interpreted in the 
context of several limitations. First, data on smoking 
tobacco use are self-reported, which might lead to 
underestimates in demographic groups with low social 
acceptability of smoking, particularly among females in 
Asia and Africa.44 Second, the scope of our study focuses 
on smoked tobacco products, and does not include 
smokeless tobacco products, e-cigarettes, heated tobacco 
products, or other electronic nicotine delivery systems. 
Incorporating the health effects of the array of emerging 
electronic nicotine delivery systems, including both 
potential benefits and potential harms, is becoming 
increasingly important. Additionally, our analysis 
focuses on the health effects of primary smoking of 
tobacco and does not include additional harms due to 
second-hand smoke. Third, we converted non-cigarette 
smoked tobacco products to cigarette-equivalents on the 
basis of the weight of tobacco. Conversion on the basis 
of health effect equivalencies would be more accurate, 
but a paucity of evidence on the health effects of 
non-cigarette tobacco products presents challenges to 
this alternative approach. Fourth, the optimal lag-time 
between exposure and outcome exceeded 10 years 
for five outcomes (ischaemic heart disease, lower 
respiratory tract infections, aortic aneurysm, peripheral 
artery disease, and peptic ulcer disease). Due to the 
paucity of data on smoking patterns before 1980, we 
were restricted to using a maximum lag-time of 10 years. 
Fifth, the rate of risk reduction among former smokers 
probably varies by smoking intensity. Although we 
captured differences in the level of risk, we did not 
capture differences in the rate of risk reduction in our 
estimates. Despite these limitations, our results are 
broadly consis tent with previous estimates that use 
different methods with a different set of limitations.20
Smoking remains a defining challenge in global 
health. Governments, and particularly ministers of 
health, face substantial obstacles ranging from popula-
tion growth, to pressure from the tobacco industry, to 
competing health and political priorities. Nevertheless, 
it is increasingly important for all countries to adopt, 
implement, and enforce com prehensive packages of 
evidence-based tobacco control policies. The current 
level of tobacco control policy implementation is 
insufficient in many countries around the world. With 
more than 1 billion people smoking tobacco globally as 
of 2019, the annual death toll, economic costs, and 
burden to health systems caused by smoking will 
increase in the years to come unless countries take 
swift and strong action to substantially reduce their 
smoking rates.
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